PDP1 and melanoma: In fact, the pre-treatment of PLX sensitive cells with DCA, a PDH activator, markedly increases the survival of PLX4032-treated cells suggesting that PDH inhibition may play a key role in sensitizing melanoma cells to PLX4032.